Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cinnamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL666959 | 0.86 | KDM4E (0.59) | MAPTKDM4ERAB9AKMT2ATDP1 | |
| Salicylic Acid SCHEMBL668244 | 0.83 | KDM4E (0.53) | KDM4EMEN1KMT2AALDH1A1HPGD | |
| Salicylic Acid SCHEMBL3468302 | 0.81 | ALDH1A1 (0.50) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| Salicylic Acid SCHEMBL17710452 | 0.79 | ALDH1A1 (0.54) | MAPTKDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL669103 | 0.79 | KMT2A (0.47) | MAPTBCHEKDM4ERAB9AMEN1 | |
| Phthalic Acid SCHEMBL5048545 | 0.77 | ALDH1A1 (0.47) | MAPTCYP2C19KDM4EMEN1KMT2A | |
| Cinnamic Acid SCHEMBL8407378 | 0.75 | MAPT (0.63) | MAPTCYP2C19BCHEKDM4ERAB9A | |
| Cinnamic Acid SCHEMBL8407375 | 0.75 | MAPT (0.63) | MAPTCYP2C19BCHEKDM4ERAB9A | |
| Cetylpyridinium SCHEMBL2369770 | 0.74 | MAPT (0.43) | MAPTCYP2C19BCHEKDM4ERAB9A | |
| Cinnamic Acid SCHEMBL28752126 | 0.74 | HDAC3 (0.70) | MAPTKDM4ERAB9AKMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-20130203602-A1 | SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS | DANMARKS TEKNISKE UNIVERSITET (DK) | 2013-08-08 | — | — | US | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203602-A1 | SUPPORTED BIOLOGICALLY ACTIVE COMPOUNDS | MIF, BMP2, BMP4 | MAPT 3938/4885CYP2C19 1830/4885BCHE 974/4885 |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | SLC6A6, SLC10A2, CLK2 | MAPT 833/4885CYP2C19 805/4885BCHE 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.